Meeting
2024 ASCO Genitourinary Cancers Symposium
Comparative cost-effectiveness of trimodal therapy and radical cystectomy for management of muscle-invasive bladder cancer.
Authors
Daniel D. Joyce
Vanderbilt University Medical Center, Nashville, TN
Daniel D. Joyce , Kevin Wymer , Stephen A. Boorjian , John L. Gore , Ali Raza Khaki , Ann Caroline Raldow , Stephen B. Williams , Angela B. Smith , Vidit Sharma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 572)
DOI
10.1200/JCO.2024.42.4_suppl.572
Abstract #
572
Poster Bd #
E21
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition (ICI) versus cisplatin-based chemotherapy (CBC) in muscle-invasive bladder cancer (MIBC).
First Author: Ali Raza Khaki
Poster
2020 Genitourinary Cancers Symposium
Cost-effectiveness of radical cystectomy versus trimodality therapy for muscle invasive bladder cancer.
First Author: Nathan Suskovic
Poster
2018 Genitourinary Cancers Symposium
Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.
First Author: Shingo Hatakeyama
Poster
2015 ASCO Annual Meeting
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
First Author: Daniel A. Goldstein